%0 Journal Article
%T The Efficacy and Safety of Yokukansankachimpihange for Treating Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer¡¯s Disease: An Open-Label Pilot Study
%A Ryutaro Arita
%A Tetsuhiro Yoshino
%A Miwako Ohgishi
%A Takuya Hamaguchi
%A Yuko Horiba
%A Kaori Sawai
%A Kei Funaki
%A Hajime Tabuchi
%A Mizuki Oka
%A Takahito Yoshizaki
%A Kenji Watanabe
%A Masaru Mimura
%J Advances in Alzheimer's Disease
%P 141-152
%@ 2169-2467
%D 2018
%I Scientific Research Publishing
%R 10.4236/aad.2018.74010
%X Previous
clinical trials have demonstrated the efficacy of yokukansan, a traditional
Japanese medicine, for the treatment of behavioral and psychological symptoms
of dementia (BPSD). However, less evidence is available for the treatment of
BPSD with yokukansankachimpihange (YKSCH), which consists of yokukansan and two
additional herbal ingredients. The present study was conducted to investigate
the efficacy and safety of YKSCH for treating BPSD in patients with Alzheimer¡¯s
disease (AD).<span style=\"font-size:10pt;font-family:;\" \"=\"\"> </span><span style=\"font-family:Verdana;\">We enrolled
outpatients with mild-to-moderate AD who exhibited BPSD and obtained a
Neuropsychiatric Inventory (NPI) score of &gt;3 including subscale scores for ¡°agitation¡±</span><span style=\"font-family:Verdana;\">, </span><span style=\"font-family:Verdana;\">¡°anxiety¡±</span><span style=\"font-family:Verdana;\">, </span><span style=\"font-family:Verdana;\">¡°irritability¡±</span><span style=\"font-family:Verdana;\">,</span><span style=\"font-family:Verdana;\"> and ¡°sleep and night</span><span style=\"font-family:Verdana;\">-</span><span style=\"font-family:Verdana;\">time behavior change¡±</span><span style=\"font-family:Verdana;\">.</span><span style=\"font-family:Verdana;\"> A daily YKSCH dose of 7.5 g was administered for 12 weeks with
concomitant administration of anti-dementia medication. BPSD w</span><span style=\"font-family:Verdana;\">as</span><span style=\"font-family:Verdana;\"> evaluated using the NPI at baseline and every 4 weeks during the
intervention. We also examined apathy using</span><span style=\"font-size:10pt;font-family:;\" \"=\"\"> </span><span style=\"font-family:Verdana;\">the Japanese translation of the Apathy Scale, the short version of the
Japanese version of the Zarit Caregiver Burden Interview, and the Modified
Crichton Rating Scale for Predicting Activities of Daily Living. Cognitive
dysfunction was evaluated using the Mini Mental State Examination and the AD
Assessment Scale-Cognitive (Japanese version).</span><span style=\"font-size:10pt;font-family:;\" \"=\"\"> </span><span style=\"font-family:Verdana;\">Five participants were enrolled. The NPI total score tended to decrease
between the baseline and 8-week evaluations during the YKSCH intervention
(Wilcoxon signed rank test, P = 0.063). In terms of the NPI subscale scores,
¡°apathy¡±</span><span style=\"font-family:Verdana;\">,</span><span style=\"font-family:Verdana;\"> ¡°agitation¡±</span><span style=\"font-family:Verdana;\">,</span><span style=\"font-family:Verdana;\"> ¡°delusion</span><span
%K Alzheimer¡¯s Disease
%K Behavioral and Psychological Symptoms of Dementia
%K Yokukansankachimpihange
%K Kampo Medicine
%K Apathy
%K Neuropsychiatric Inventory
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=89050